Key Highlights0.13 is the loss per share in USD implied by the consensus EPS estimate of -0.13 for TuHURA Biosciences, Inc. (NASDAQ:HURA), which reports third quarter 2026 results before the market opens on November 13, 2026.8.7 million USD is the combined second quarter 2026Research …
Key HighlightsOpenAI'sRevenuereportedly rose about 50% to roughly USD 10 billion in the third quarter of 2026, the first time it has topped that level in a single quarter.The company's operating loss widened to about USD 10.9 billion from USD 10.1 billion in the prior …
Key HighlightsThird-quarter net sales rose 4.7% to USD 459.8 million, while the net loss was USD 32.5 million, or USD 0.40 per diluted share, against a loss of USD 19.1 million, or USD 0.24, a year earlier.A USD 40.7 million non-cashImpairmenton the B&M and …
The Rationale: Last Reported Quarter and Management Outlook for Neumora Therapeutics, Inc. (NASDAQ:NMRA)
Key HighlightsExpedia Group (NASDAQ:EXPE) fell 3.0% on November 10, 2026, while Booking Holdings dropped 2.1% and Airbnb 2.3%, after reports that OpenAI had acquired AI travel planning platform Odessia.Odessia's chief executive confirmed publicly that the company had been acquired by OpenAI; financial terms were …
The trust owns apartments, build-to-rent communities and single-family homes in Sunbelt and Western markets, and as a REIT it reports funds from operations (FFO). Diluted FFO was negative USD 4.6 million in the quarter against negative USD 3.9 million, and nine-month FFO was negative …
In the second quarter, company-owned comparable sales rose 11.4% andFranchisecomparable sales rose 5.5%. Adjusted EBITDA was USD 10.8 million versus USD 6.0 million, restaurant contributionMarginwas 17.2% versus 12.8%, andOperating Marginwas -1.2% versus -11.7%. Six-month revenue was USD 250.8 million and the net loss was …
Key HighlightsSoftBank Group (OTC:SFTBY) swung to a net loss of about 1.1 trillion yen, or roughly USD 7 billion, for the July to September quarter, missing every analyst forecast and reversing a 2.5 trillion yen profit a year earlier.The result included a USD 3.7 …
The company is a clinical-stage diabetes and obesity medicinesBusinesswhose lead candidate, icovamenib, is an oral small molecule in Phase II. Nine-monthResearch and Developmentfell 50% to USD 26.8 million, calculated, with the nine-month net loss at USD 26.9 million against USD 66.4 million. Spending shifted …
Per the screener snapshot, Flexible Solutions International, Inc. reports third quarter 2026 results on November 13, 2026, after the market closes, with a consensus EPS estimate of 0.19 and a market capitalization of USD 82.91 million. The estimate implies a return to profit from …